PYPD Polypid

PolyPid Announces Presentation at the 2022 Military Health System Research Symposium

PolyPid Announces Presentation at the 2022 Military Health System Research Symposium

Efficacy Data of D-PLEX100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation

PETACH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data and animal study data for D-PLEX100 in surgical trauma injuries will be highlighted in a podium presentation at the 2022 Military Health System Research Symposium (MHSRS) being held on September 12-15, 2022, at the Gaylord Palms Resort and Convention Center, Kissimmee, Florida.

The 2022 Military Health System Research Symposium:

Title: D-PLEX100, a doxycycline releasing antimicrobial product for surgical site wounds, reduces surgical site infection rates and drug resistant-bacteria in surgical trauma injuries.
Presenter:Noam Emanuel, PhD, Co-Founder and Chief Scientific Officer, PolyPid.
Date:Monday, September 12, 2022

The abstract will be available on  following the presentation.

About PolyPid

(Nasdaq: ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on and .

Contacts: 

PolyPid Ltd. 

Ori Warshavsky

COO – US

908-858-5995

Investors:

Bob Yedid

LifeSci Advisors

646-597-6989

Media Contact:

Nechama Feuerstein

551-444-0784

 



EN
30/08/2022

Underlying

PYPDPolypid

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Polypid

 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Provides Corporate Update and Reports First Quarter 2025 Finan...

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company ai...

May 14, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Report First Quarter 2025 Financial Results and Operational...

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business ope...

April 29, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid to Participate in The Citizens Life Sciences Conference PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025. Citizens Life Sciences Conference Fireside ChatDate:Wednesday, May 7, 2025Time:10:30 AM ET   The PolyPid management team will participate in one-on-one investor meetings duri...

April 22, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIEL...

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections Last Patient Enrolled Following Positive Recommendation by DSMB to Conclude Enrollment of Phase 3 Trial at 800 Patients; Top-line Results Expected by End of Q2 2025 and, if Positive, Expected to be Followed by Submission of an NDA to the FDA Leveraging the Company’s Fast-Track and Breakthrough Therapy Designations PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“PolyPid” or the “Company”), a late-stage bio...

March 11, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid to Participate in the 37th Annual ROTH Conference PETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the 37th Annual ROTH Conference taking place in Dana Point, California, from March 17-18, 2025. PolyPid’s fireside chat will be available on-demand beginning on Monday, March 17, 2025, at 2:00 PM PT via the conference platform using the following . The PolyPid management team will par...

March 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch